Baxter Healthcare Corp. will temporarily import from the United Kingdom certain amino acid drugs in short supply in the United States, beginning with limited quantities in the next few weeks, the Food and Drug Administration announced last week. In other news, FDA last week released draft guidance aimed at making it easier for brand and generic drug companies to implement a shared risk evaluation and mitigation strategy. FDA can require drugs associated with serious risks to implement a REMS with elements to assure safe use. In such cases, current law requires brand and generic drug companies to try to reach agreement on a shared system REMS. “As we work to make it easier to engage in a shared system REMS, we’ll be looking more specifically at how we can address situations where innovator firms may be leveraging the single, shared system REMS requirement to block or delay generic competition,” said FDA Commissioner Scott Gottlieb, M.D. The agency will accept comments on the draft guidance through Jan. 8.

Related News Articles

Headline
Members of the pharmaceutical distribution supply chain, including dispensers such as hospitals and pharmacies, can apply through March 11 to participate in a…
Headline
The U.S. District Court for the Western District of Pennsylvania has entered a consent decree prohibiting Ranier’s Rx Laboratory Inc. from manufacturing or…
Headline
The Food and Drug Administration Friday warned physicians and patients who use medical devices to monitor levels of the blood thinner warfarin that certain…
Headline
The AHA today submitted to the Food and Drug Administration legislative, regulatory and best practice recommendations to address new and chronic prescription…
Headline
The Food and Drug Administration yesterday released revised draft guidance for facilities that compound human drugs as outsourcing facilities.
Headline
The AHA, American Society of Anesthesiologists, American Society of Clinical Oncology, American Society of Health-System Pharmacists, and Institute for Safe…